In a decisive step toward scale, Little Green Pharma has secured nearunanimous support to acquire 100% of Cannatrek, a move that signals growing consolidation across the medicinal cannabis sector.
At the Scheme Meeting held on 10 April 2026, Cannatrek shareholders delivered a resounding endorsement of the transaction. Over 96% of shareholders present and voting backed the deal, representing more than 98% of total votes cast. In markets where conviction can be hard to come by, this level of alignment stands out.
A Clear Path to Completion
The transaction now moves to the next critical step, with approval from the Federal Court of Australia scheduled for 24 April 2026. Subject to court approval, the scheme is expected to become effective the same day, with implementation targeted for 1 May
Why It Matters
The combination positions LGP to strengthen its footprint in the medicinal cannabis market, bringing together cultivation, manufacturing, and distribution capabilities under one roof. Watch this space.
